Carl G. Kardinal

5.5k total citations · 1 hit paper
71 papers, 3.9k citations indexed

About

Carl G. Kardinal is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Carl G. Kardinal has authored 71 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 17 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carl G. Kardinal's work include Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (13 papers) and HER2/EGFR in Cancer Research (9 papers). Carl G. Kardinal is often cited by papers focused on Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (13 papers) and HER2/EGFR in Cancer Research (9 papers). Carl G. Kardinal collaborates with scholars based in United States, Canada and India. Carl G. Kardinal's co-authors include James E. Krook, Norman Wolmark, Richard G. Margolese, James B. Gerstner, Loren K. Tschetter, James A. Mailliard, Harry S. Wieand, J A Mailliard, Ralph Levitt and Nikolay V. Dimitrov and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Carl G. Kardinal

66 papers receiving 3.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial

1999 724 citations Norman Wolmark, Carl G. Kardinal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carl G. Kardinal United States	27	2.4k	1.4k	680	661	589	71	3.9k
John W. Kugler United States	32	2.6k 1.1×	605 0.4×	1.4k 2.1×	490 0.7×	703 1.2×	62	4.5k
G.H. Blijham Netherlands	35	2.3k 1.0×	738 0.5×	1.2k 1.7×	502 0.8×	1.1k 1.8×	88	4.6k
Tom R. Fitch United States	34	2.0k 0.8×	813 0.6×	1.3k 1.9×	652 1.0×	1.2k 2.0×	97	4.6k
Christos Markopoulos Greece	33	2.5k 1.0×	1.7k 1.2×	615 0.9×	569 0.9×	1.0k 1.7×	198	4.7k
J.W.R. Nortier Netherlands	44	3.5k 1.5×	1.9k 1.4×	1.2k 1.8×	783 1.2×	952 1.6×	157	7.8k
Peter D. Eisenberg United States	34	2.8k 1.2×	925 0.7×	1.4k 2.0×	314 0.5×	903 1.5×	80	5.5k
Philip J. Stella United States	39	3.3k 1.4×	780 0.6×	2.1k 3.1×	757 1.1×	1.0k 1.7×	126	5.6k
Loren K. Tschetter United States	32	2.2k 0.9×	306 0.2×	1.1k 1.6×	406 0.6×	507 0.9×	61	3.7k
Marina Elena Cazzaniga Italy	28	2.1k 0.9×	609 0.4×	639 0.9×	389 0.6×	540 0.9×	138	3.2k
Noriyuki Katsumata Japan	38	2.8k 1.1×	708 0.5×	811 1.2×	533 0.8×	776 1.3×	183	5.7k

Countries citing papers authored by Carl G. Kardinal

Since Specialization

Citations

This map shows the geographic impact of Carl G. Kardinal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl G. Kardinal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl G. Kardinal more than expected).

Fields of papers citing papers by Carl G. Kardinal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl G. Kardinal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl G. Kardinal. The network helps show where Carl G. Kardinal may publish in the future.

Co-authorship network of co-authors of Carl G. Kardinal

This figure shows the co-authorship network connecting the top 25 collaborators of Carl G. Kardinal. A scholar is included among the top collaborators of Carl G. Kardinal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl G. Kardinal. Carl G. Kardinal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kardinal, Carl G., et al.. (2012). Outcomes of male breast cancer in the United States: A SEER database analysis from 1973 to 2008.. Journal of Clinical Oncology. 30(15_suppl). 1586–1586. 1 indexed citations

Kardinal, Carl G., et al.. (2012). The Changing Hope Trajectory in Patients With Advanced-Stage Cancer: A Nursing Perspective. Clinical journal of oncology nursing. 16(3). 241–242. 2 indexed citations

Hamm, John, John Wilson, Priya Rastogi, et al.. (2008). Gemcitabine/Epirubicin/Paclitaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group. Clinical Breast Cancer. 8(3). 257–263. 8 indexed citations

Okuno, Scott H., Jeff A. Sloan, Nathan R. Foster, et al.. (2008). A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma. Cancer. 112(8). 1772–1779. 14 indexed citations

Kardinal, Carl G.. (2006). Hurricane katrina: the challenge to cancer clinical research.. PubMed Central. 1 indexed citations

Long, Harry J., Robert A. Nelimark, Karl C. Podratz, et al.. (2005). Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Gynecologic Oncology. 100(3). 501–505. 10 indexed citations

Perez, Edith A., Vera J. Suman, Kendrith M. Rowland, et al.. (2005). Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252. Clinical Breast Cancer. 6(5). 425–432. 99 indexed citations

Jatoi, Aminah, Nathan R. Foster, Patricia Johnson, et al.. (2004). Investigating four ‘myths’ surrounding dysphagia in patients with metastatic esophageal cancer. a multi-institutional study from the North Central Cancer Treatment Group*. Diseases of the Esophagus. 17(4). 292–296. 7 indexed citations

Smith, Roy E., Stewart Anderson, Ann Brown, et al.. (2002). Phase II Trial of Doxorubicin/Docetaxel/Cyclophosphamide for Locally Advanced and Metastatic Breast Cancer: Results from NSABP Trial BP-58. Clinical Breast Cancer. 3(5). 333–340. 20 indexed citations

10.

Perez, Edith A., David W. Hillman, Philip J. Stella, et al.. (2000). A phase II study of paclitaxel plus carboplatin as first‐line chemotherapy for women with metastatic breast carcinoma. Cancer. 88(1). 124–131. 13 indexed citations

11.

Ingle, James N., Vera J. Suman, Carl G. Kardinal, et al.. (1999). A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer. 85(6). 1284–1292. 53 indexed citations

12.

Peters, George N., Carl G. Kardinal, A. Robidoux, & Gabriel N. Hortobágyi. (1995). Inflammatory breast cancer: what is the appropriate therapy for patients who have a clinical response to induction chemotherapy?. PubMed. 22(5). xiv, xxi, xxvi, xxxii–xiv, xxi, xxvi, xxxii. 2 indexed citations

13.

Buckner, Jan C., Loren D. Brown, John W. Kugler, et al.. (1995). Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. Journal of neurosurgery. 82(3). 430–435. 49 indexed citations

14.

Jett, James R., Andrew W. Maksymiuk, John Q. Su, et al.. (1994). Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.. Journal of Clinical Oncology. 12(11). 2321–2326. 95 indexed citations

15.

Kardinal, Carl G.. (1994). The Randomized Clinical Trial. Oncology Issues. 9(5). 3–3. 5 indexed citations

16.

Maksymiuk, Andrew W., James R. Jett, John D. Earle, et al.. (1994). Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial.. Journal of Clinical Oncology. 12(1). 70–76. 53 indexed citations

17.

Veeder, Michael H., James R. Jett, John Q. Su, et al.. (1992). A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 70(9). 2281–2287. 26 indexed citations

18.

Kardinal, Carl G. & William L. Donegan. (1980). Second cancers after prolonged adjuvant thiotepa for operable carcinoma of the breast. Cancer. 45(8). 2042–2046. 18 indexed citations

19.

Kardinal, Carl G.. (1979). Introduction: Historic milestones in cancer research. Seminars in Oncology. 6(4). 395. 1 indexed citations

20.

Kardinal, Carl G., et al.. (1977). Reactions of Patients with Advanced Cancer to Their Diagnosis and Treatment. Military Medicine. 142(5). 374–376. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact